SOA Wealth Advisors LLC. Boosts Stock Position in Cencora, Inc. (NYSE:COR)

SOA Wealth Advisors LLC. increased its stake in Cencora, Inc. (NYSE:COR) by 211,666.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,353 shares of the company’s stock after buying an additional 6,350 shares during the period. SOA Wealth Advisors LLC.’s holdings in Cencora were worth $1,767,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently made changes to their positions in the stock. Lpwm LLC purchased a new stake in Cencora during the 1st quarter valued at $269,000. Patriot Financial Group Insurance Agency LLC increased its stake in Cencora by 6.5% in the 1st quarter. Patriot Financial Group Insurance Agency LLC now owns 4,481 shares of the company’s stock worth $1,246,000 after buying an additional 275 shares in the last quarter. UMB Bank n.a. increased its stake in Cencora by 16.7% in the 1st quarter. UMB Bank n.a. now owns 1,457 shares of the company’s stock worth $405,000 after buying an additional 209 shares in the last quarter. Gateway Investment Advisers LLC increased its stake in Cencora by 11.4% in the 1st quarter. Gateway Investment Advisers LLC now owns 9,964 shares of the company’s stock worth $2,771,000 after buying an additional 1,021 shares in the last quarter. Finally, Pines Wealth Management LLC purchased a new stake in Cencora in the 1st quarter worth $234,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Insider Buying and Selling

In other Cencora news, CAO Lazarus Krikorian sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $260.06, for a total value of $520,120.00. Following the completion of the transaction, the chief accounting officer now owns 20,154 shares of the company’s stock, valued at $5,241,249.24. This trade represents a 9.03% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Chairman Steven H. Collis sold 14,579 shares of the firm’s stock in a transaction that occurred on Tuesday, April 22nd. The shares were sold at an average price of $281.81, for a total transaction of $4,108,507.99. Following the completion of the transaction, the chairman now directly owns 315,913 shares of the company’s stock, valued at $89,027,442.53. This represents a 4.41% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 40,253 shares of company stock worth $11,102,417 in the last 90 days. Insiders own 10.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on COR shares. Morgan Stanley set a $288.00 price target on Cencora in a research note on Tuesday, April 15th. Robert W. Baird increased their price target on shares of Cencora from $314.00 to $350.00 and gave the company an “outperform” rating in a report on Thursday, May 8th. UBS Group increased their price target on shares of Cencora from $298.00 to $335.00 and gave the company a “buy” rating in a report on Tuesday, April 29th. Wall Street Zen raised shares of Cencora from a “hold” rating to a “buy” rating in a report on Wednesday, March 12th. Finally, Citigroup increased their price target on shares of Cencora from $330.00 to $355.00 and gave the company a “buy” rating in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $306.91.

Cencora Price Performance

NYSE:COR opened at $289.01 on Friday. Cencora, Inc. has a one year low of $218.65 and a one year high of $309.35. The company has a debt-to-equity ratio of 16.40, a quick ratio of 0.54 and a current ratio of 0.92. The firm has a market cap of $56.02 billion, a price-to-earnings ratio of 41.11, a PEG ratio of 1.31 and a beta of 0.58. The firm’s fifty day moving average is $286.29 and its two-hundred day moving average is $260.27.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 EPS for the quarter, beating the consensus estimate of $4.07 by $0.35. The company had revenue of $75.50 billion for the quarter, compared to analyst estimates of $75.41 billion. Cencora had a net margin of 0.46% and a return on equity of 328.62%. The firm’s revenue was up 10.3% on a year-over-year basis. During the same period in the prior year, the company earned $3.80 earnings per share. Research analysts expect that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, June 2nd. Investors of record on Friday, May 16th were given a dividend of $0.55 per share. The ex-dividend date of this dividend was Friday, May 16th. This represents a $2.20 annualized dividend and a dividend yield of 0.76%. Cencora’s dividend payout ratio (DPR) is presently 25.52%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.